Join
Live feed
·
PRReleasevia Quantisnow
Vaccinex Inc. logo

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

ByQuantisnow·Wall Street's wire, on your screen.
VCNX· Vaccinex Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VCNX (Vaccinex Inc.) and more on Quantisnow.